

An Review on Antibiotic Resistance

Drx. Ghansavant Shweta Jayram

Swargiya Lilawati Satish Awhad College of Pharmacy, Mukhed, Nanded

Abstract: *Antibiotic resistance is one of the most serious global public health challenges of the modern era. It occurs when bacteria develop the ability to survive and multiply despite the use of antibiotics that were previously effective against them. The inappropriate and excessive use of antibiotics in human healthcare, veterinary medicine, agriculture, and animal farming has significantly accelerated the emergence of resistant microorganisms. As a result, many bacterial infections have become more difficult to treat, leading to prolonged illness, increased healthcare costs, and a higher risk of complications and death.*

Microorganisms possess the ability to adapt through genetic mutations and the exchange of resistance genes, allowing them to overcome the action of antimicrobial drugs. The continuous spread of resistant bacteria has reduced the effectiveness of many commonly used antibiotics and has created a major challenge for healthcare systems worldwide. Furthermore, the limited development of new antibiotics by pharmaceutical industries has made the problem even more critical.

This review discusses the origin, mechanisms, major types, and clinical impact of antibiotic resistance. It also highlights the different classes of antibiotics, their therapeutic applications, and the importance of responsible antibiotic use in preventing the further spread of antimicrobial resistance.

Keywords: Antibiotic resistance, Antimicrobial resistance, Bacteria, Antibiotics, Drug resistance, Public health.

I. INTRODUCTION

The discovery of antibiotics is considered one of the greatest achievements in modern medicine. Since their introduction, antibiotics have played a vital role in treating bacterial infections, reducing disease-related complications, and saving millions of lives worldwide. These drugs either kill bacteria or inhibit their growth, making them highly effective in the management of infectious diseases.

However, the widespread and inappropriate use of antibiotics has led to the emergence of antibiotic resistance. Antibiotic resistance occurs when bacteria undergo genetic changes that enable them to survive despite exposure to antibiotics that were once effective. As resistant bacteria continue to multiply, infections become more difficult to treat, increasing the risk of prolonged illness, treatment failure, and mortality.

The development and rapid spread of multidrug-resistant bacteria have become a major concern for healthcare systems across the world. Factors such as self-medication, overuse of antibiotics, incomplete treatment courses, and misuse in agriculture and animal husbandry have accelerated this problem. Therefore, rational antibiotic use, continuous surveillance, infection control measures, and the development of new antimicrobial agents are essential to combat the growing threat of antibiotic resistance.

II. ORIGIN OF ANTIBIOTIC RESISTANCE

Antibiotic resistance develops when bacteria acquire the ability to survive the action of antibiotics. This resistance may occur naturally or may be acquired through genetic changes and the transfer of resistance genes between bacteria. The continuous exposure of bacteria to antibiotics increases the selection of resistant strains, making infections more difficult to treat.



1. Natural Selection

When antibiotics are used, susceptible bacteria are eliminated, while resistant bacteria survive and continue to multiply. Over time, these resistant organisms become more common within the bacterial population.

2. Genetic Mutations

Random changes in the bacterial DNA may produce characteristics that help bacteria resist the effects of antibiotics. These mutations are inherited by subsequent generations, allowing resistance to persist.

3. Horizontal Gene Transfer (HGT)

Bacteria can exchange genetic material, including resistance genes, through plasmids and other mobile genetic elements. This process enables resistance to spread rapidly between different bacterial species.

4. Target Site Modification

Some bacteria develop changes in the structure of antibiotic target sites, such as ribosomes or specific enzymes. These modifications reduce the ability of antibiotics to bind effectively, resulting in decreased drug activity and treatment failure.

The increasing spread of antibiotic-resistant bacteria in both hospital and community settings has become a major public health concern.

Continuous monitoring, appropriate antibiotic use, and effective infection control measures are essential to limit the development and transmission of resistance.

III. TYPES OF ANTIBIOTIC RESISTANCE

Antibiotic resistance can be classified into different types based on how bacteria develop or acquire the ability to resist antimicrobial drugs.

1) Intrinsic Resistance (Natural Resistance).

Intrinsic resistance is the natural ability of certain bacteria to resist the action of specific antibiotics because of their inherent structural or physiological characteristics. For example, the outer membrane of many Gram-negative bacteria prevents certain antibiotics from entering the cell.

Example: Escherichia coli shows natural resistance to Vancomycin.

2) Acquired Resistance (Secondary Resistance)

Acquired resistance develops when bacteria that were previously susceptible become resistant after exposure to antibiotics. This usually occurs due to genetic mutations or the acquisition of resistance genes through horizontal gene transfer.

Example: Mycobacterium tuberculosis developing resistance to Rifampicin and Ethanbutol.

3) Cross Resistance

Cross resistance occurs when resistance to one antibiotic also provides resistance to other antibiotics belonging to the same class or having a similar mechanism of action.

Example: Resistance to Penicillin may also reduce the effectiveness of certain Cephalosporin.

4) Multidrug Resistance (MDR)

Multidrug resistance refers to the ability of bacteria to resist the action of multiple antibiotics belonging to different classes. This type of resistance significantly limits treatment options and is a major concern in clinical practice.

Example: Staphylococcus aureus (MDR strains).


5) Adaptive Resistance

Adaptive resistance is a temporary form of resistance that develops when bacteria are exposed to environmental stress or certain antibiotics. This resistance may disappear once the stress is removed



Example: Adaptive resistance observed during treatment with Imipenem under specific environmental conditions. Understanding the different types of antibiotic resistance is essential for selecting appropriate antimicrobial therapy and implementing effective infection control strategies to reduce the spread of resistant microorganisms.

MECHANISMS OF ANTIBIOTIC RESISTANCE



IV. MECHANISM OF ANTIBIOTIC RESISTANCE

Antibiotic resistance develops through several biological mechanisms that enable bacteria to survive in the presence of antimicrobial drugs. These mechanisms reduce the effectiveness of antibiotics and make bacterial infections more difficult to treat. How Antibiotic Resistance Spreads

1. DNA Mutations

Spontaneous changes in the bacterial DNA may alter important cellular structures or functions. These genetic mutations can make bacteria less susceptible to antibiotics and are passed on to future generations during bacterial multiplication.

2. Horizontal Gene Transfer (HGT)

Bacteria can transfer resistance genes to one another through plasmids and other mobile genetic elements. This process allows antibiotic resistance to spread rapidly among different bacterial species.

V. MAIN MECHANISMS OF ANTIBIOTIC RESISTANCE

1. Drug Inactivation or Modification

Some bacteria produce enzymes that chemically destroy or modify antibiotics before they reach their target site, making the drugs ineffective.

Example: Beta-lactamase enzymes hydrolyze beta-lactam antibiotics such as Penicillin.

2. Target Site Alteration

Bacteria may modify the structure of antibiotic target sites, including ribosomes or penicillin-binding proteins. As a result, antibiotics cannot bind effectively, leading to reduced drug activity.

Example: Methicillin-resistant *Staphylococcus aureus* (MRSA) alters its penicillin-binding proteins.



3. Reduced Permeability

Certain bacteria decrease the permeability of their cell membrane or outer membrane, preventing antibiotics from entering the bacterial cell in sufficient amounts.

Example: Pseudomonas aeruginosa and some strains of Escherichia coli show reduced permeability to Carbapenems.

4. Active Efflux Pumps

Many bacteria possess membrane transport proteins known as efflux pumps that actively expel antibiotics from the cell before the drugs can exert their antibacterial effect.

5. Metabolic Bypass

Some bacteria develop alternative metabolic pathways that bypass the biochemical process targeted by an antibiotic. This allows bacterial growth to continue even in the presence of the drug.

Understanding these mechanisms is essential for developing effective treatment strategies, improving antibiotic stewardship, and reducing the global spread of antimicrobial resistance.

VI. CLASSES OF ANTIBIOTICS AND THEIR USES

Antibiotics are classified according to their chemical structure and mechanism of action. Different classes of antibiotics are used to treat specific types of bacterial infections.

1. Beta-Lactam Antibiotics (Penicillins and Cephalosporin)

Beta-lactam antibiotics inhibit bacterial cell wall synthesis, leading to the death of susceptible bacteria. Resistance commonly occurs due to the production of betalactamase enzymes that destroy the beta-lactam ring.

Examples: Amoxicillin, Ampicillin, Penicillin

Uses:

- Streptococcal throat infections
- Ear infections
- Urinary tract infections (UTIs)

2. Macrolides

Macrolides inhibit bacterial protein synthesis by acting on the ribosomal subunit. They are commonly used in patients who are allergic to penicillin.

Examples: Azithromycin, Erythromycin,

Clarithromycin **Uses:**

- Respiratory tract infection
- Sexually transmitted infections (STIs)
- Pneumonia

3. Fluoroquinolones (Quinolones)

Fluoroquinolones interfere with bacterial DNA replication by inhibiting DNA gyrase and topoisomerase enzymes.

Examples: Ciprofloxacin, Levofloxacin

Uses:

- Urinary tract infections
- Gastrointestinal infections
- Certain respiratory tract infections



4. Tetracycline

Tetracycline inhibit bacterial protein synthesis and have broad-spectrum antibacterial activity.

Examples: Doxycycline, Tetracycline, Minocycline

Uses:

- Acne vulgaris
- Lyme disease
- Various skin and systemic infections

5. Glycopeptides

Glycopeptides are particularly effective against Gram-positive bacteria and act by inhibiting cell wall synthesis.

Examples: Vancomycin, Teicoplanin, Oritavancin, Dalbavancin

Uses:


- Bone and joint infections
- Complicated skin and soft tissue infections
- Infective endocarditis (infection of the heart lining or valves)

Knowledge of different antibiotic classes and their clinical applications is important for selecting appropriate therapy and reducing the development of antibiotic resistance.

VII. GRAPHICAL REPRESENTATION OF ONSET OF ANTIBIOTIC RESISTANCE VERSUS TIME

The graph illustrates the gradual development of antibiotic resistance over time. Initially, antibiotics are highly effective in controlling bacterial infections. However, repeated, excessive, and inappropriate use of antibiotics creates selective pressure on bacteria, allowing resistant strains to survive and multiply.

As resistance increases, the effectiveness of antibiotics gradually declines, making infections more difficult to treat. This trend highlights the importance of rational antibiotic use, continuous surveillance, infection prevention, and the development of new antimicrobial agents to slow the progression of antibiotic resistance.



VIII. ANTIBIOTICS WHICH INHIBIT METABOLIC PATHWAYS

Certain antibiotics inhibit essential metabolic pathways in bacteria, preventing the synthesis of important cellular components required for bacterial growth and survival.

1. Sulfonamides

Sulfonamides are bacteriostatic antibiotics that inhibit the synthesis of folic acid by competing with para-amino benzoic acid (PABA). Since folic acid is essential for the formation of nucleic acids, inhibition of this pathway prevents bacterial growth and multiplication.

Example: Sulfathiazole

Mechanism of Action:

- Competes with PABA during folic acid synthesis.
- Inhibits the production of tetrahydrofolic acid (THFA).
- Prevents the synthesis of purines and pyrimidines required for DNA formation.

Adverse Effect:

May cause Stevens–Johnson Syndrome in susceptible individuals.

2. Trimethoprim

Trimethoprim inhibits the bacterial enzyme dihydrofolate reductase, blocking a later step in folic acid synthesis. This further reduces bacterial DNA synthesis and cell multiplication.

Mechanism of Action:

- Inhibits dihydrofolate reductase.
- Prevents the formation of tetrahydrofolic acid (THFA).
- Interferes with bacterial DNA synthesis.

Uses:

- Effective against many Gram-negative bacteria.
- Commonly used in combination with Sulfamethoxazole (Co-trimoxazole) for enhanced antibacterial activity.
- Used in the treatment of urinary tract infections, Pneumocystis jirovecii pneumonia, and No cardia infections.

3. Lipopeptides

Lipopeptides are bactericidal antibiotics that act by disrupting the bacterial cell membrane. They cause rapid membrane depolarization, resulting in leakage of intracellular ions and inhibition of DNA, RNA, and protein synthesis, ultimately leading to bacterial cell death.

Example: Daptomycin

Mechanism of Action:

- Binds to the bacterial cell membrane.
 - Causes membrane depolarization.
 - Stops DNA, RNA, and protein synthesis.
- Results in rapid bacterial cell death.

Uses:

- Treatment of infections caused by Gram-positive bacteria, including MRSA and other resistant organisms.
- Effective in skin and soft tissue infections, bloodstream infections, and infective endocarditis.



- These antibiotics target essential metabolic processes or bacterial cell membranes, making them valuable in the treatment of serious bacterial infections while helping to overcome certain resistance mechanisms.
 - Competes with PABA during folic acid synthesis.
 - Inhibits the production of tetrahydrofolic acid (THFA).
- Prevents the synthesis of purines and pyrimidines required for DNA formation.

Adverse Effect:

May cause Stevens–Johnson Syndrome in susceptible individuals.

2. Trimethoprim

Trimethoprim inhibits the bacterial enzyme dihydrofolate reductase, blocking a later step in folic acid synthesis. This further reduces bacterial DNA synthesis and cell multiplication.

Mechanism of Action:

- Inhibits dihydrofolate reductase.
- Prevents the formation of tetrahydrofolic acid (THFA).
- Interferes with bacterial DNA synthesis.

Uses:

- Effective against many Gram-negative bacteria.
- Commonly used in combination with Sulfamethoxazole (Co-trimoxazole) for enhanced antibacterial activity.
- Used in the treatment of urinary tract infections, Pneumocystis jirovecii pneumonia, and No cardia infections.

3. Lipopeptides

Lipopeptides are bactericidal antibiotics that act by disrupting the bacterial cell membrane. They cause rapid membrane depolarization, resulting in leakage of intracellular ions and inhibition of DNA, RNA, and protein synthesis, ultimately leading to bacterial cell death.

Example: Daptomycin

Mechanism of Action:

- Binds to the bacterial cell membrane.
 - Causes membrane depolarization.
 - Stops DNA, RNA, and protein synthesis.
- Results in rapid bacterial cell death.


Uses:

- Treatment of infections caused by Gram-positive bacteria, including MRSA and other resistant organisms.
 - Effective in skin and soft tissue infections, bloodstream infections, and infective endocarditis.
- These antibiotics target essential metabolic processes or bacterial cell membranes, making them valuable in the treatment of serious bacterial infections while helping to overcome certain resistance mechanisms.

IX. ADVERSE EFFECTS OF ANTIBIOTIC RESISTANCE

Antibiotic resistance has serious consequences for both patients and healthcare systems. Resistant bacterial infections are more difficult to treat and often require stronger or multiple antibiotics. This may lead to prolonged illness, extended hospital stays, increased treatment costs, and a higher risk of complications. In severe cases, antibiotic resistance can result in treatment failure and increased mortality. It also contributes to the rapid spread of resistant bacteria within hospitals and communities, making infection control more challenges.





X. CONCLUSION

Antibiotic resistance has become a major global public health concern. The inappropriate and excessive use of antibiotics has accelerated the emergence of resistant bacteria, reducing the effectiveness of many commonly used antimicrobial drugs. Promoting the rational use of antibiotics, strengthening infection control practices, improving surveillance programs, and encouraging the development of new antibiotics are essential steps to limit the spread of resistance. Public awareness and responsible prescribing practices are equally important in preserving the effectiveness of existing antibiotics for future generations.

REFERENCES

1. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms, and clinical relevance. Marana MC, Moreira B, Boyle-Vavra S, et al. Infect Dis Clin North Am.
2. A brief history of the antibiotic era: lessons learned and challenges for the future. Amino RI. Front Microbiol. 2010;1:134. doi: 10.3389/fmicb.2010.001
3. Origins and evolution of antibiotic resistance. Davies J, Davies D. Microbiol Mol Biol Rev.
4. Varghese J, Roberts JA, Lipmann J. Current Opinion in Anesthesiology. 2010; 23:472-478
5. South African Antibiotic Stewardship Programme 2015. Wasserman S, Boyles T and Mendelson M.
6. Prasetyoputri A, Jarrad AM, Cooper MA, Blaskovich MAT. Trends in Microbiology 2019; 27:339-354
7. Cunha CB, Opal SM. Medical Clinics of North America. 2018; 102:831-843
8. Udy AA et al. Crit Care Med 2014; 42:520-527
9. De Wale JJ et al. Int Care Med 2014; 40:1340-1351
10. Richards GA, Joubert IA, Brink AJ. S Afr Med J 2015; 105:419
11. www. Google.com
12. World Health Organization (WHO). Priority Medicines for Europe and the World/Warren Kaplan, Richard Laing 2004. Available online
13. Livermore, D.M. Bacterial Resistance: Origins, Epidemiology, and Impact. Clin. Infect.
14. Clardy, J.; Fischbach, M.A.; Currie, C.R. The natural history of antibiotics. Curr. Biol.
15. Anderson RM, May R. Oxford. Publication Google; 1991. Infectious diseases of humans.

